// App-Quantinova.ai

450 : Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis

Researchers

Presenter

  • Craig C. Hofmeister

Principal Investigators

  • David S. Siegel

  • Ravi Vij

  • Sagar Lonial

  • Kenneth C. Anderson

  • Min Chen

  • Mohamed Zaki

  • Paul G. Richardson

Medical Centers

  • Mount Sinai Medical Center, New York, NY

Locations

  • United States

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Multiple Myeloma

  • Acute lung injury

  • Infant Respiratory Distress Syndrome

  • Urinary tract infections

  • Peripheral neuropathy

  • Deep vein thrombosis

  • Thrombocytopenia

  • Neutropenia

  • Depression

  • Venous thrombosis

  • Dyspnea

  • Anemia

Biomarkers

  • Granulocyte colony-stimulating factor

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • Bortezomib

  • Aspirin

  • Albyl-E

  • Filgrastim

Outcome

  • N/A

Study Design

  • randomized

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved